We describe an enzymatic fluorometric method for determining glucose concentrations
0.986).
One of the most common assays done in clinical laboratories is the determination of glucose. Hence, it is desirable to have a rapid, inexpensive, yet accurate and precise method for the measurements. The use of hexokinase (EC 2.7.1.1) and glucose-6-phosphate dehydrogenase (BC 1.1.1.49) for the selective assay of glucose has been widely adopted (1) (2) (3) (4) (5) (6) because of its high specificity. The siliconerubber pad method developed by this laboratory, in which all the reagents for the assay are lyophilized on the surface of the pad, provides advantages of simplicity and economy (7).
Here, we have applied the pad method to the hexokinase/glucose-6-phosphate dehydrogenase system. No incubation is required and only 5 jl of blood sample is needed for a glucose determination. Syringes (Hamilton Co., Reno, Nev. 89502), 10-and l00-il, were used to apply plasma (or serum), substrate, and water onto the pads.
Materials and Methods

Reagents
Preparation of Reagent Pads
The reagent pads were prepared and stored in a manner similar to that described by Kuan et al. (7), except that 2 ml of the ice-cold Tris buffer was added to the enzyme and NADP+ reagent vials, respectively, for reconstitution. 
Results and Discussion
Analytical Variables
Precision. at least three days without any deterioration, no matter whether they were stored at -20 or 4 #{176}C in a desiccator (Table 1) . Recovery studies were verified by the use of a pool plasma sample and a Moni-Trol I control serum to which various amounts of glucose standard were added.
Addition of 0.50 to 1.50 g of glucose to plasma or serum, to a total of 1.37 to 2.34 g/liter, showed a percent recovery of 96 to 103% (Table 2) .
Interference.
The hexokinase/glucose-6-phosphate dehydrogenase method provides a high degree of freedom from interference by substances in blood (4). We found that uric acid (<1 g/liter), mannose (<1 g/liter), ascorbic acid (<10 g/liter), and fructose (<20 gfliter) do not interfere.
Comparison.
The glucose concentration in 50 fresh plasma samples determined by the present method and by the o-toluidine method (9). Acceptable correlation was obtained (Figure 2) , the correlation coefficient being 0.986. 
Negligible Interference by Spironolactone and Prednisone in Digoxin Radioimmunoassay
Richard Ravel
Spironolactone and prednisone reportedly cause measurable values for apparent digoxin, even when none is present. Effects of these medications were evaluated with 1251-labeled digoxin kits from five different manufacturers. Values obtained for apparent digoxin were either negligible or not sufficiently great to be clinically significant, regardless of kit methodology or manufacturer.
Addftlonal Keyphrase: '*It" methods Serum digoxin assay is being requested more and more frequently.
Reports indicate that chances of digitalis toxicity are considerably increased when digoxin concentrations in blood are not monitored to see how closely the quantity in blood after therapeutic dosage approaches a toxic concentration (1, 2) . Other uses include assistance in diagnosis of toxicity and as an indication that a patient may be omitting medication.
As is the case for most laboratory tests, results must be interpreted in the context of the clinical find- A few reports (3, 6) and information in digoxin kits from several manufacturers (7-9) indicate that spironolactone and prednisone display the greatest potential for cross-reactivity among medications thus far investigated.
Phillips (4) and Zeegers et al. (6) confirmed that these two drugs may in fact produce laboratory error in digoxin 
Materials and Methods
Ten patients were selected who were receiving oral spironolactone (Aldactone or Aldactazide, G. D. Searle and Co.), 25 mg twice a day. I also selected the following patients on oral prednisone: 10 who were receiving 10 mg three or four times a day, one who was receiving 15 mg of prednisone once a day, one receiving 20 mg once a day, two receiving 25 mg twice a day, and one receiving 50 mg twice a day. Most of these patients had never received digitalis compounds, and none had taken digitalis for at least three weeks. Specimens were drawn 2 h after the last therapeutic dose, on the assumption that absorption would then be maximum.1 Each patient's serum specimen was assayed by 1-125 kits from each of the following five manufacturers: Clinical Assays ("Gammacoat"; Clinical Assays, Inc., Cambridge, Mass. 02142); Corning ("Immunophase"; Corning Co., Medfield, Mass. 02052); Kallestad ("Quantitope,"
1-125 Digoxin; Kallestad Laboratories, Chaska, Minn. 55318); Mallinckrodt ("RIA-MAT" Digoxin 1-125; Mallinckrodt Nuclear, Inc., Maryland Heights, Mo. 63043); and Schwarz-Mann ("Digoxin 1-125"; Schwarz-Mann Co., Orangeburg, N. Y. 10962). These kits represent most of the current techniques for separating bound and free radioactive antigen (solidphase, double antibody, resin strip, and dextran-coated charcoal). For some specimens, determinations were made in different laboratories with a kit supplied by the same manufacturer. Specimens that could not be tested immedi-
